New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

New research suggests adiposity and access to education may be clinically relevant modifiable mediators of 

 risk attributable to reproductive factors.

The 2-sample and 2-step Mendelian randomization (MR) analysis explored the impact of major reproductive factors on the risk of psoriasis, including overall psoriasis, psoriasis vulgaris (PV), and 

, while accounting for the potential mediation effect of 4 confounders: body mass index (BMI), years of education, tobacco use, and alcohol consumption level.

“To the best of our knowledge, the association and mechanisms involved in the relationship between reproductive factors and psoriasis have not been fully elucidated, and there are no studies of causal intermediates or mediators,” Yajia Li, of the department of dermatology and the National Clinical Research Center for Geriatric Disorders at Xiangya Hospital in China, and colleagues wrote.

Psoriasis affects an estimated 3% of the adult population ≥ 20 years of age in the US, or more than 7.5 million adults.

 Understanding modifiable risk factors is essential for preventing the onset and managing the adverse health outcomes associated with psoriasis. While hormone-induced factors have previously been identified, studies investigating the association between modifiable reproductive factors and the incidence of psoriasis are sparse.

To explore the association between reproductive traits and risk of psoriasis and the mediated proportion of the total causal effects of known confounders, investigators conducted a 2-sample MR study using summarized statistics from the genome-wide association studies (GWAS) conducted in reproductive traits as well as GWAS data on overall psoriasis, PsA, and PV.

Investigators identified 7 different factors for the exposure datasets, including age at menarche (AMA, 243,944 individuals), age at menopause (AMP, 143,819 individuals), age at first birth (AFB, 542,901 individuals), age at last live birth (ALB, 170,248 individuals), number of live births (NEB, 250,782 individuals), age at first sexual intercourse (AFS, 397,338 individuals), and lifetime number of sexual partners (NSP, 378,882 individuals).

Psoriasis (216,752 individuals including 4510 cases and 212,242 controls), PsA (213,879 individuals including 1,637 cases and 212,242 controls), and PV (215,044 individuals including 2802 cases and 212,242 controls) data were obtained from the FinnGen Biobank Analysis Consortium database.

Acknowledging the complex clinical and genetic backgrounds of the psoriasis cases, investigators merged 4 potential confounders previously shown to be associated with the exposure and outcome to construct an multivariable MR and a 2-step mediation MR model to adjust the mediation effect; these included BMI (99,998 individuals), years of education (766,345 individuals), tobacco consumption (249,752 individuals), and alcohol consumption level (462,346 individuals).

Strongly associated single nucleotide polymorphisms were filtered out using a stringent genome-wide significance threshold of 

 < 5 × 10-8 to ensure the relevance assumption.

In univariable MR analysis, only AFS demonstrated a significant protective effect on psoriasis (odds ratio [OR], 0.54; 95% CI, 0.41-0.72; 

 = .000), consistent with the results obtained using the CAUSE method (OR, 0.71; 95% CI, 0.63-0.80; 

 = .002). Of note, this causal effect lost significance after correcting BMI (OR, 0.66; 95% CI, 0.48-1.12; 

 = .113) and education (OR, 0.71; 95% CI, 0.48-1.06; 

 = .096), and further analysis revealed 36.13% and 47.79% of this effect was mediated through BMI and educational attainment, respectively.

Additionally, AFB showed a significant negative association with PsA (OR, 0.76; 95% CI, 0.64-0.92; 

 = .003) in the univariable MR, consistent with the results of the CAUSE method (OR, 0.87; 95% CI, 0.82-0.92; 

 = .038). Further 2-step analysis revealed a partial mediating effect of BMI on the association between AFB and PsA, with a 49.61% proportion of the mediation attributable to BMI.

AFS also had a significant negative effect on PV (OR, 0.38; 95% CI, 0.27-0.55; 

 <.001), which aligned with findings from the CAUSE method (OR, 0.60; 95% CI, 0.55-0.65; 

 <.001). A partial but nonsignificant mediating effect was found for BMI on AFS-PV (indirect effect OR, 0.78; 95% CI, 0.45-1.33; 

 = .352; proportion of mediation, 26.27%), while the direct effect of AFS (OR, 0.44; 95% CI, 0.30 to 0.66; 

“Greater efforts to reduce adiposity and improve access to education appear to be clinically relevant,” investigators concluded.

 “In addition, further research is needed to identify other environmental risk factors that act as potentially modifiable mediators of psoriasis. Modifying these factors may help substantially reduce the burden of psoriasis risk that is attributable to reproductive factors.”

Li Y, Li Q, Cao Z, et al. The Impact of Reproductive Traits on Psoriasis Risk is Mediated by Education Attainment and Body Mass Index: A Mendelian Randomization Study. 

National Psoriasis Foundation. Prevalence of Psoriasis. Accessed April 22, 2025. 

https://www.psoriasis.org/prevalence-of-psoriasis/

Articles

New research indicates that adiposity and educational access may be significant modifiable mediators of psoriasis risk linked to reproductive factors. A Mendelian randomization analysis examined the impact of reproductive traits on psoriasis risk, considering confounders like BMI, education, tobacco, and alcohol use. The study found that age at first sexual intercourse and age at first birth had protective effects against psoriasis and psoriatic arthritis, respectively, with BMI and education mediating these effects. The findings suggest targeting adiposity and education could reduce psoriasis risk associated with reproductive factors.

Findings suggest BMI and education levels could be clinically relevant modifiable mediators of psoriasis risk attributable to reproductive factors.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Reproductive Traits Linked to Psoriasis Risk But Mediated By BMI, Education

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Hanna M. Knauss, MD, Beth Israel Deaconess Medical Center | Image Credit: X

A recent secondary analysis of the Dietary Approaches to Stop Hypertension (DASH)-Sodium trial has indicated that sodium reduction and the DASH diet independently and additively reduced 10-year 

atherosclerotic cardiovascular disease (ASCVD)

“While the [DASH-Sodium] trial found that sodium reduction and the DASH diet independently improved blood pressure, the effects of these dietary interventions on 10-year ASCVD risk were not assessed,” wrote Hanna M. Knauss, MD, department of medicine, Beth Israel Deaconess Medical Center, and colleagues. “We hypothesized that sodium reduction alone would decrease risk and that the combined effect of sodium reduction with the DASH diet would be additive.”

The original DASH-Sodium trial was a randomized controlled trial including 412 adults ≥22 years, all of whom had elevated blood pressure or hypertension. They were randomly assigned to 12 weeks of either a standard American diet or the DASH diet, which centered around fruits, vegetables, and low-fat dairy while reducing saturated fat and cholesterol. Measurements of high-sensitivity cardiac troponin I, NT-proBNP, and hs-CRP were taken at baseline and 4, 8, and 12 weeks after randomization.

The DASH diet led to a statistically significant decrease in high-sensitivity cardiac troponin I (17.78%; 95% CI, -29.51% to -4.09%, 

 = .01%) and hs-CRP (19.97%; 95% CI, -31.94% to -5.89%, 

 = .01%) at week 12 compared to control. From these data, researchers determined that the DASH diet reduces biomarkers of subclinical cardiac injury and inflammation over time.

Knauss and colleagues compared the results of the DASH-Sodium trial to the effects of solely lowering sodium levels. Their trial collected 412 participants of mean age 48 +/- 10 years and 57% female. However, at the point of analysis, 22 were missing covariates necessary for an ASCVD risk calculation and were excluded, leaving 390 participants in this secondary trial. The same diets were utilized, although participants were additionally randomized to one of three sodium levels within each diet – low, medium, or high.

All participants were initially assigned to the high-sodium diet for a 2-week run-in period, followed by randomization to respective diets and sodium levels. Participants then consumed each level of sodium for an average of 30 days; each period was separated by a 5-day-average washout period to resume normal diets.

Knauss and colleagues found that mean 10-year ASCVD risk score at baseline was 3.13% in the control diet and 2.63% in the DASH diet. By the end of the trial, the DASH diet exhibited an absolute difference of -.12% (95% CI, -.23 to -.02) and a relative difference of -5.33% (95% CI, -9.32 to -1.16).

Notably, however, the team indicated that there was no evidence that diet had any effect on the effects of low sodium intake on risk (

-interaction = .26). Instead, they provided the overall results, indicating that low sodium level changed ASCVD risk by -.34% (95% CI, -.45 to -.23) among the control diet and -.17% (95% CI, -.25 to -.08) in the DASH diet. Medium sodium level changed ASCVD risk by -.19% (95% CI, -.29 to -.09) in control and -.09% (95% CI, -.18 to -.01) in the DASH diet.

However, despite the optimistic appearance of these data, Knauss and colleagues point out the limitations of their study. First, they utilized a relatively short follow-up period with each sodium intervention lasting only 30 days. Second, individuals with known heart disease, renal insufficiency, diabetes mellitus, and those on antihypertensive treatment were excluded: many Americans meet one or more of these exclusion criteria. Given these limitations, investigators call for further action to be taken in monitoring and promoting healthy diets and habits.

“These effects were additive when combining both interventions versus either alone,” Knauss and colleagues wrote. “Our findings reinforce the need for public efforts to promote adoption of DASH eating habits and sodium reduction to mitigate CVD risk.”

Knauss HM, Kovell LC, Miller ER 3rd, et al. Dietary sodium reduction lowers 10-year atherosclerotic cardiovascular disease risk score: Results from the DASH-sodium trial. 

. 2025;22:100980. Published 2025 Mar 27. doi:10.1016/j.ajpc.2025.100980

Belanger MJ, Kovell LC, Turkson-Ocran RA, et al. Effects of the Dietary Approaches to Stop Hypertension Diet on Change in Cardiac Biomarkers Over Time: Results From the DASH-Sodium Trial. 

. 2023;12(2):e026684. doi:10.1161/JAHA.122.026684

A secondary analysis of the DASH-Sodium trial revealed that both sodium reduction and the DASH diet independently and additively decreased 10-year ASCVD risk. The trial involved 412 adults with elevated blood pressure, comparing a standard American diet to the DASH diet, which emphasizes fruits, vegetables, and low-fat dairy. The DASH diet significantly reduced biomarkers of cardiac injury and inflammation. Despite the positive findings, the study's limitations include a short follow-up period and exclusion of individuals with certain health conditions, prompting calls for further research and public health efforts.

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Limiting Sodium Intake Can Reduce Atherosclerotic Cardiovascular Disease Risk

This month’s Lungcast features a discussion on lung cancer screening guidelines and pulmonary nodule management. 

Lung Cancer Screening: A Decade of Lessons Learned with Mary Pasquinelli, DNP

Lung cancer remains the leading cause of cancer-related death worldwide, accounting for nearly 2 million deaths annually, which is more than those caused by breast, colorectal, and cervical cancers combined. Despite this burden, only 15% of patients survive 5 years post-diagnosis, largely due to late-stage detection in the majority of cases. It has been more than a decade since lung cancer screening guidelines via low-dose CT, based on the USPSTF’s B recommendations, have been put into place. 

In the latest episode of Lungcast, host Albert Rizzo, MD, chief medical officer of the American Lung Association (ALA), discussed this topic on the monthly respiratory health podcast series. Rizzo spoke with Mary Pasquinelli, DNP, a nurse practitioner in the Division of Pulmonary, Critical Care, Sleep, and Allergy at University of Illinois Health. She also serves as the director of the Lung Screening Program at the University of Illinois Chicago.

In this episode of Lungcast, Rizzo and Pasquinelli discussed the guidelines’ ambitions and obstacles. They also discussed pulmonary nodule management, which, while a lifesaving procedure for at-risk individuals, has seen slower than expected the uptake of screening on a population-level, although this is increasing. Pasquinelli also outlined a number of efforts and tools to increase screening rates.

“Screening truly saves lives, and we have all these efforts underway to really enhance screening through refined criteria, risk stratification, integration of emerging tools like biomarkers and AI such as Sybil, which holds really great, great promise for improving early detection and outcomes. So, it's just so important that we remember that anybody with lungs can get lung cancer. And thankfully, the narrative around lung cancer is changing. There's more awareness, there's more innovation, and more, most importantly, there's more hope,” Pasquinelli stressed.

Lungcast is a monthly respiratory news podcast series hosted by Albert Rizzo, MD, chief medical officer of the ALA, and produced by 

Videos

Strategic Alliance Partnership

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Topline results from the Phase 3 ARISE trial showed xanomeline and trospium chloride (Cobenfy) added no significant benefit over placebo as an adjunctive treatment to typical antipsychotics for 

treatment, announced Bristol Myers on April 22, 2025.

“Although Cobenfy did not demonstrate a statistically significant improvement as an adjunctive treatment in this trial, the data are encouraging, showing a noteworthy improvement for the majority of patients in the trial, as well as a tolerable safety profile,” said Husseini Manji, MD, FRCPC, co-chair of the UK Government Mental Health Goals Program and a psychiatry professor at Oxford University, in a statement.

The US Food and Drug Administration (FDA) approved Cobenfy for schizophrenia back on September 26, 2024, marking it as the first pharmacological approach to treating schizophrenia since the 1970s and the first antipsychotic drug to target cholinergic, not dopamine, receptors.

 After those pivotal phase 3 EMERGENT trials, the company conducted ARISE (KAR-012), a phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study evaluating the efficacy and safety of xanomeline and trospium chloride vs placebo as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia.

 The trial included adults aged 18 to 65 years with schizophrenia who were on a stable antipsychotic at the time of enrollment, with a stable Positive and Negative Syndrome Scale (PANSS) score of ≥ 70 at screening.

In ARISE, xanomeline and trospium chloride demonstrated a 2.0-point reduction in the PANSS total score compared to placebo with an atypical antipsychotic at week 6. Preliminary analyses demonstrated that xanomeline and trospium chloride vs placebo as an adjunctive treatment was linked to improvements in schizophrenia symptoms.

Despite numerical reductions, xanomeline and trospium chloride as an adjunctive treatment to typical antipsychotics did not reach a statistically significant difference in the PANSS total score, compared to taking typical antipsychotics with placebo (-14.3 vs -12.2; least squares mean difference [LSMD], -2.0; 95% confidence interval [CI], -4.5 to 0.5; P = .11).

A post-hoc subgroup analysis also showed a notable difference between participants treated with risperidone and those treated with a different background antipsychotic. When patients took risperidone with xanomeline and trospium chloride or placebo, patients had slightly more PANSS total score reductions on risperidone and adjunctive placebo (-12.3 vs 11.3; LSMD, 1.1, 3.7 to 5.9; P = .66. However, when patients took an antipsychotic other than risperidone, participants had signficantly greater PANSS reductions on the antipsychotic plus xanomeline and trospium chloride than the antipsychotic plus placebo (-15 vs -11.7; LSMD, -3.4; -6.3 to -0.5; P = .03).

Xanomeline and trospium chloride’s safety and tolerability profile as an adjunctive treatment aligned with earlier trials.

“These findings warrant additional follow up and may provide valuable direction in our ongoing search for complementary approaches to address these persistent treatment gaps,” Manji said.

Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia. Bristol Myers Squibb. April 22, 2025. 

https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-ARISE-Trial-Evaluating-Cobenfy-xanomeline-and-trospium-chloride-as-an-Adjunctive-Treatment-to-Atypical-Antipsychotics-in-Adults-with-Schizophrenia/default.aspx

Derman, C. Bristol Myers Squibb Shares EMERGENT-4, EMERGENT-5 Results on Cobenfy for Schizophrenia. HCPLive. November 1, 2024. 

https://www.hcplive.com/view/fda-approves-xanomeline-and-trospium-chloride-cobenfy-for-schizophrenia

The Phase 3 ARISE trial results indicated that xanomeline and trospium chloride (Cobenfy) did not significantly outperform placebo as an adjunctive treatment to typical antipsychotics for schizophrenia. Despite the lack of statistical significance, the trial showed a promising improvement in symptoms for many patients and maintained a tolerable safety profile. The FDA had previously approved Cobenfy as a novel treatment targeting cholinergic receptors. A post-hoc analysis revealed significant PANSS score reductions when used with non-risperidone antipsychotics, suggesting potential benefits in specific patient subgroups.

Xanomeline and trospium chloride failed to show significant benefit as an adjunctive schizophrenia treatment to typical antipsychotics but showed promise in select subgroups.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Cobenfy Falls Short in Phase 3 ARISE Trial as Adjunctive Schizophrenia Therapy

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

 prevalence among the oldest-old adults within the US, new findings suggest, with increases in atopic dermatitis cases among older adults by 85.53% from 1990 - 2019.

These findings further suggested mixed gender-related disparities among such patients, with higher age-specific rates of prevalence among males and cases among females. Minmin Wang—from the Department of Global Health at the Peking University School of Public Health in Beijing—led the team of investigators in the analysis that led to these results.

“In the present study, we aimed to evaluate the sex disparities in prevalence and influencing factors among the US oldest-old adults,” Wang and colleagues wrote.

“Our findings may provide valuable insights for the management of elderly [atopic dermatitis] among this population.”

The study’s investigators looked at older adult patients aged 80-84, 85-89, 90-94, and 95 years and older. They assessed US-based prevalence data on atopic dermatitis in the period from 1990 - 2019, with the necessary data being collected from the Global Burden of Disease (GBD) 2019 study.

The team assessed rates of atopic dermatitis prevalence as well as the number of disease cases, exploring the epidemiological profile of atopic dermatitis among this older population of subjects. They also projected future trends from 2020 - 2030 through the use of a Bayesian age-period-cohort model.

The analysis examined trends over time by various factors such as calculated male-to-female case ratios, sex, and used age-period-cohort modeling stratified by sex to isolate the impacts on the results of timeframe, age, and birth cohort on shifts in the disease's prevalence. Quantification of the roles of population growth, aging, and prevalence rate shifts in driving the rise in atopic dermatitis cases was done using Das Gupta's decomposition method.

The investigators concluded that between 1990 - 2019, the number of disease cases in this age cohort rose by 85.53%, with a larger absolute and relative increase being identified by the study among males—126.09% compared to 63.39% in females. The investigative team noted that the forecasts suggest continuation of this upward trend, with approximately 467,700 cases being likely by 2030.

In all of the evaluated age brackets, women were shown to have made up the majority of cases, with the team highlighting male-to-female case ratios ranging from 0.40 - 0.85. This pattern was highlighted by the research team as a “high-female case disparity," although there has been a gradual reduction in the sex gap since 1990.

The age-standardized prevalence rate (ASPR) for atopic dermatitis as of 2019 in this elderly cohort was noted by the team as 2,471.79 per 100,000 patients. From 1990 - 2019, an increase in ASPR at an average annual rate of 0.14% took place, with males reporting a slightly quicker rise (0.13% per year) versus the 0.08% per year rise among females.

Men were noted by the investigators as showing consistently higher rates of disease prevalence across all 4 of the previously highlighted age groups, with male-to-female prevalence rate ratios showing a range from 1.10 - 1.45. This was referred to in the study as a “high-male rate disparity," and it was more pronounced in the older age groups.

The investigative team expressed that the age effect component of their modeling confirmed higher age-specific prevalence rates seen among males, which they noted aligns with the observed “high-male rate disparity.” Comparable patterns were shown in both sexes by period and cohort effects. Population rises were pointed to as the predominant factor impacting the rising number of cases.

Overall, the study found a sustained rise in both the number of atopic dermatitis cases and prevalence rates among the oldest-old adults in the US, as well as suggesting a dual pattern of sex disparity. Nevertheless, the team highlighted their research's potential limitations in their conclusion.

“This study had several limitations,” they wrote.

 “Detailed information on [atopic dermatitis] was not available in the GBD database, such as data on risk factors, which prevented further analyses. Additionally, we do not have access to prevalence data of [atopic dermatitis] by states, and we are unable to analyse the regional distribution of prevalence.”

Wang, M., Cao, X., Zhou, M., Mi, Y., Yu, P. and Guo, Y. (2025), Mixed Sex Disparities in Elderly Atopic Dermatitis Prevalence Among US Oldest-Old Adults: A Longitudinal Study. Clin Exp Allergy. 

Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” Lancet 396, no. 10258 (2020): 1204–1222, 

https://doi.org/10.1016/s0140-6736(20)30925-9

The prevalence of atopic dermatitis among the oldest-old adults in the US has increased by 85.53% from 1990 to 2019, with a notable rise in cases among males compared to females. The study, led by Minmin Wang, analyzed data from the Global Burden of Disease 2019 study, using a Bayesian age-period-cohort model to project future trends. The findings indicate a dual pattern of sex disparity, with males showing higher prevalence rates, while females account for more cases. Population growth and aging are key factors driving the increase in cases.

This study highlights the different sex-related disparities as well as those among older adults with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Sustained Rise Observed in Atopic Dermatitis Cases, Prevalence Rates in Older US Adults

Study findings highlight regional variability in the prevalence of PBC in the US in 2021, additionally suggesting potential barriers to specialist care.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Study Highlights Regional Variability in PBC Prevalence, Limited Specialist Care Access

Connor Iapoce is the assistant managing editor for 

joining the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to the movies, and playing with his cat, Squish. You can reach him at 

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

FDA News

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

FDA Awards Breakthrough Device Designation to AVIM Therapy for Hypertension

The model could allow cardiologists to inform and prepare patients before symptoms of hypertrophic cardiomyopathy make themselves known.

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

AI Algorithm Used to Predict Odds of Hypertrophic Cardiomyopathy

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Participants in the cytisinicline group also had a significantly greater reduction in smoking urges.

Cytisinicline Significantly Helped People Who Smoke Remain Abstinent

Panelists discuss how treatment approaches for C3 glomerulopathy (C3G) have evolved from nonspecific immunosuppression to targeted complement inhibition, with the recent FDA approval of iptacopan marking a significant advancement in disease management.

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Personalizing C3G Treatment: Insights From Experienced Clinicians

Panelists discuss how C3 glomerulopathy (C3G) is triggered by factors like infections or pregnancy that activate the alternative pathway in genetically predisposed individuals, presenting with diverse clinical manifestations that often overlap with other glomerular diseases, making diagnosis challenging without kidney biopsy.

The Cost of Diagnostic Delay of C3G Across Age Groups

Christie M. Ballantyne, MD, discusses the role of plozasiran in managing elevated triglycerides and reducing pancreatitis risk.

Dyslipidemia

Triglyceride Management and Pancreatitis Risk, With Christie M. Ballantyne, MD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

This SOCS News Update was filmed on-site at the 2025 AAD meeting, highlighting Nambudiri’s work and the launch of the AAD Clinical Image Collection.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: New Update—Discussing the AAD Clinical Image Collection

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Antibiotic Use In Infants Linked to Greater Asthma, Allergy Risk

Fola May, MD, PhD, is an associate professor at the David Geffen School of Medicine and associate director of the UCLA Kaiser Permanente Center for Health Equity.

May describes differences between colorectal cancer screening tests and which might be right for patients based on their preferences and values.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Latest News

Reproductive Traits Linked to Psoriasis Risk But Mediated By BMI, Education

Limiting Sodium Intake Can Reduce Atherosclerotic Cardiovascular Disease Risk

Lung Cancer Screening: A Decade of Lessons Learned with Mary Pasquinelli, DNP

Cobenfy Falls Short in Phase 3 ARISE Trial as Adjunctive Schizophrenia Therapy

Sustained Rise Observed in Atopic Dermatitis Cases, Prevalence Rates in Older US Adults